Helomics® to Present at Biotech Showcase 2016 during the J. P. Morgan HealthCare Conference

PITTSBURGH–(BUSINESS WIRE)–Helomics Corporation, a privately held comprehensive personalized
healthcare company that develops innovative next generation diagnostics
for the oncology field, announced today that it will present at the
Biotech Showcase 2016 to be held January 11-13, 2016, at the Parc 55 San
Francisco.

Neil Campbell, President and CEO of Helomics, will provide an overview
of the Company’s personalized tumor profiling business during his live
presentation and will be available to participate in one-on-one meetings
with investors who are registered to attend the conference.

Event:           Biotech Showcase 2016
Date: Tuesday, January 12, 2016
Time: 2:30pm (Pacific Time)
Location: Parc 55 San Francisco, Track E, Room Davidson

About Helomics® Corporation

Helomics® is a comprehensive personalized healthcare company,
bringing the next generation of diagnostics to the oncology field.
Helomics is dedicated to improving patient outcomes by providing a
comprehensive personalized tumor profile utilizing a proprietary set of
laboratory platforms that leverage both live and fixed cellular analysis
to allow physicians to personally characterize malignant tumors.
Helomics’ novel molecular and cellular markers and bioinformatics
services are designed to support treatment decisions by providing vital
information based on the specific biological processes of each
individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company
maintains two CLIA-certified laboratories. For more information please
visit: www.helomics.com.

Contacts

Tiberend
Strategic Advisors, Inc.

Investors
Joshua Drumm, Ph.D.,
212-375-2664
jdrumm@tiberend.com
or
Media
Claire
Sojda, 212-375-2686
csojda@tiberend.com